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Background People from racial minority groups in western countries experience 
disproportionate socioeconomic and structural determinants of health disadvantag-
es. These disadvantages have led to inequalities and inequities in health care access 
and poorer health outcomes. We report disproportionate disparities in prevalence, 
hospitalisation, and deaths from COVID-19 by racial minority populations.
Methods We conducted a systematic literature search of relevant databases to iden-
tify studies reporting on prevalence, hospitalisations, and deaths from COVID-19 
by race groups between 01 January 2020 – 15 April 2021. We grouped race cate-
gories into Blacks, Hispanics, Whites and Others. Random effects model using the 
method of DerSimonian and Laird were fitted, and forest plot with respective ratio 
estimates and 95% confidence interval (CI) for each race category, and subgroup 
meta-regression analyses and the overall pooled ratio estimates for prevalence, hos-
pitalisation and mortality rate were presented.
Results Blacks experienced significantly higher burden of COVID-19: prevalence ra-
tio 1.79 (95% confidence interval (CI) = 1.59-1.99), hospitalisation ratio 1.87 (95% 
CI = 1.69-2.04), mortality ratio 1.68 (95% CI = 1.52-1.83), compared to Whites: 
prevalence ratio 0.70 (95% CI = 0.0.64-0.77), hospitalisation ratio 0.74 (95% 
CI = 0.65-0.82), mortality ratio 0.82 (95% CI = 0.78-0.87). Also, Hispanics experi-
enced a higher burden: prevalence ratio 1.78 (95% CI = 1.63-1.94), hospitalisation 
ratio 1.32 (95% CI = 1.08-1.55), mortality ratio 0.94 (95% CI = 0.84-1.04) compared 
to Whites. A higher burden was also observed for Other race groups: prevalence ratio 
1.43 (95% CI = 1.19-1.67), hospitalisation ratio 1.12 (95% CI = 0.89-1.35), mortal-
ity ratio 1.06 (95% CI = 0.89-1.23) compared to Whites. The disproportionate bur-
den among Blacks and Hispanics remained following correction for publication bias.
Conclusions Blacks and Hispanics have been disproportionately affected by 
COVID-19. This is deeply concerning and highlights the systemically entrenched 
disadvantages (social, economic, and political) experienced by racial minorities in 
western countries; and this study underscores the need to address inequities in these 
communities to improve overall health outcomes.
Cite as: Mude W, Oguoma VM, Nyanhanda T, Mwanri L, Njue C. Racial 
disparities in COVID-19 pandemic cases, hospitalisations, and deaths: A 
systematic review and meta-analysis. J Glob Health 2021;11:05015.
In December 2019, a new pneumonia-like infection with varying symptoms, ranging 
from mild to severe shortness of breath, emerged from Wuhan, China [1]. A World 
Health Organisation (WHO) investigation designated the infection as a 2019 novel 
coronavirus and was subsequently named COVID-19 [2]. The infection quickly spread 
throughout the world; at the time of writing, the source has not yet been determined. 
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2020 and became a pandemic in March [3,4]. Transmission occurs through air droplets, and no proven cure 
had existed against the virus. As of 24 May 2021 at 2:50 pm Central European Summer Time (CEST), there have 
been 166 860 081 confirmed COVID-19 infection cases and 3 459 996 related deaths worldwide and rising [5].
Available evidence suggests that medical comorbidities, obesity, diabetes, old age, and being a male are risk 
factors for COVID-19 [6,7]. However, in countries where data has been reported for race, the data shows that 
the burdens of COVID-19 are disproportionately high among racial minority groups [6,8]. For example, in 
the United Kingdom, the United States of America, and Brazil, high cases of COVID-19 are reported in peo-
ple from racial minority groups [9-12]. The reports show that in the United Kingdom and the United States 
of America, 35% and 33% of COVID-19 patients, respectively, are from racial minority populations [7,10], 
although these populations make much lower proportions of the total population. Some experts have claimed 
these disproportionately high burdens of COVID-19 are a result of health disparities and entrenched inequi-
ties experienced by minority communities [13]. However, conflicting findings relating to the reported bur-
den of COVID-19 by racial groups have shown different rates. Some reports have claimed that White popu-
lations have higher mortality than Blacks, Asian, and Minority Ethnic (BAME) groups, while others showed 
that BAME groups have higher cases or no differences [14-16]. A recently published systematic review by Pan 
and colleagues [17] suggests that Blacks have a high risk of acquiring COVID-19 infection and worse clinical 
outcomes than Whites. However, the systematic review conducted by Pan and colleagues [17] did not run a 
meta-analysis and only summarised finding from each of the studies without synthesising them to highlight 
the extent of the issue.
In this article, we report our systematic review and meta-analysis of the literature on the burden of COVID-19 
by race. We assessed the disparity of COVID-19 prevalence, hospitalisation and mortality ratios among Blacks, 
Hispanics, Whites, and Other race groups. This review provides vital information on the burdens of COVID-19 
among the selected race group and will help support policies that address health inequities.
METHODS
Search strategy
Our search strategy was guided by the PRISMA statement [18]. We conducted the systematic search strategy 
in the following databases and conference proceedings: CINAHL Complete, Medline, Web of Science (Sci-
ence Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Arts & Humanities 
Citation Index (A&HCI), Conference Proceedings Citation Index- Science (CPCI-S), Conference Proceedings 
Citation Index- Social Science & Humanities (CPCI-SSH), and Emerging Sources Citation Index (ESCI)) for 
peer-reviewed papers published between 1 January 2020 – 15 April 2021. We searched these databases and 
conference proceedings using the search terms: TI(prevalence OR incidence OR burden* OR rate* OR death* 
OR Mortali*) AND (COVID-19 OR 2019 novel coronavirus disease OR COVID19 OR COVID-19 pandemic 
OR SARS-CoV-2 infection OR COVID-19 virus disease OR 2019 novel coronavirus infection OR 2019-nCoV 
infection OR coronavirus disease 2019 OR coronavirus disease-19 OR 2019-nCoV disease OR COVID-19 virus 
infection) AND (people of colo* OR minor* OR immigrant* OR African American OR Hispanics OR black* OR 
emigrant* OR ethnic). We also searched grey literature and government websites for COVID-19 data by race.
Outcomes
The primary outcomes assessed were COVID-19 prevalence, hospitalisations, and deaths by the following se-
lected race categories: Blacks, Hispanics, Whites, and Other race groups. Blacks were defined as people with 
African ancestral origins who self-identify or are identified as Black, African or Afro-Caribbean [19,20]. Whites 
were described as people with European ancestral origins who identify or are identified as White non-Hispan-
ic [20]. Hispanics were defined as people of Spanish speaking backgrounds from Central and South America 
who identify or are identified by others as Hispanic or Latino. Other race groups were defined as race groups 
not identified as Whites, Hispanics or Blacks (Asians, Indigenous, mixed-race, and unknown). Few COVID-19 
studies have categorised Asians as a separate racial group when examining COVID-19 outcomes by race. Be-
cause of this, we have grouped Asian in “Other race groups”.
Screening and appraisal
The lead author, the third co-author and the last co-author conducted the search and screening process sep-
arately, identifying studies by titles and abstracts. Studies that reported race data on prevalence or deaths or 
hospitalisations were included in this study. Studies were excluded if they were commentaries, letters, reviews, 
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and opinions. At the same time, studies that reported prev-
alence, deaths, and hospitalisation for other health condi-
tions were excluded. After removing the duplicates, studies 
were screened by titles, abstracts and read in full. Studies 
that met the inclusion criteria (Figure 1) were appraised for 
quality using the JBI quality appraisal for systematic litera-
ture reviews [21].
Data extraction and meta-analysis
We independently extracted information from studies that 
met the inclusion criteria. Information on the author, year 
of publication, country, study design, race, population pro-
portion, samples, cases, prevalence, deaths, and hospital-
isation was extracted, where appropriate. We separated the 
studies into four different race groups: Blacks, Hispanics, 
Whites, and Other race groups (Asians, Indigenous, mixed-
race, and others).
We calculated the expected number of cases, hospitalisa-
tions, and deaths for each study, where appropriate. We 
used the expected number of cases, hospitalisations, and 
deaths to calculate the prevalence, hospitalisation, and mor-
tality rate ratios weighted by the population of each race 
group. Where population proportion for race category was 
not provided, we used respective country census data (USA 
[22] and UK [23]) to determine each race proportion to establish weighted prevalence ratio, hospitalisation 
ratio, and mortality rate.
We assumed that the probability for the occurrence of the expected cases, hospitalisations and deaths was the 
same as the probabilities for the occurrence of the observed cases, hospitalisations, and deaths in the absence 
of any changes in the rate of infectivity and the risk of exposure. We also assumed that all members of the 
population were at risk of infection, hospitalisations, and deaths from COVID-19 because no vaccination had 
existed at the time and that the pattern of the outbreak was random. That is, people randomly took up testing 
for COVID-19 from drive-by testing centres and hospitals, and therefore the reported samples were represen-
tative of the population group.
We calculated 95% confidence intervals (CI) using both the exact Poisson distribution approach for observed 
and expected counts <100 and the approach for observed and expected counts >100 [24]. Random effects 
model using DerSimonian and Laird’s methods were fitted, and forest plot with respective ratio estimates and 
95% CI were presented for each race category in subgroup analyses and the overall pooled ratio estimates for 
prevalence, hospitalisation and mortality. The -statistic was used to test the overall effect with statistical signif-
icance set at α≤0.005 Heterogeneity between studies was assessed using the I2 statistic. Nonparametric trim-
and-fill analysis was used to assess for publication bias [25,26]. Multivariable meta-regression was performed 
to explore heterogeneity resulting from the relationship between study effect sizes and race, country, year, and 
study design. The metan Stata module in Stata 16.1 MP (StataCorp, College Station, TX, USA) was used to 
conduct the meta-analysis [27].
RESULTS
Studies
We included 72 studies that reported at least observed cases, hospitalisations, or deaths from COVID-19. The 
included studies and the period covered by each study are provided in Table S1 in the Online Supplementa-
ry Document. Fifty-four studies (75.0%) were from the United States of America, 13 (18.1%) from the Unit-
ed Kingdom, and five (6.9%) from Brazil. Forty-four studies were cohorts (61.1%), 10 reports (13.9%), 17 
cross-sectional (23.6%) and one case-control (1.4%). Twelve studies (16.2%) reported the observed cases, hos-
pitalisations, and deaths [28-40]. Ten studies (13.5%) reported observed hospitalisations and deaths [41-50], 
and eight studies (12.2%) reported cases and deaths [34,51-58]. Two studies (2.8%) reported observed cases 
and hospitalisations [59,60]. Seventeen studies (22.6%) reported observed cases only [61-77]. Twelve studies 
(16.2%) reported hospitalisations [78-88], and 11 (14.9%) reported deaths only [12,89-98].
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102 duplicates removed. 
224 studies for eligibility. 
44 cohorts 
152 studies were excluded because: 
- 26 were commentaries and opinions.
- 15 were editorials.
- 80 were news media.
- 3 did not have full text.
- 21 were reviews.
- 7 did not have relevant data.72 studies were included. 









10 reports 17 cross-sectional 1 case-control 
115 studies removed by 
titles and abstracts. 
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COVID-19 prevalence ratio
Thirty-nine studies (54.2%) (22 cohorts [28-32,34,36,40,52-57,59,62,63,66,67,73-75], ten cross-sectional 
[35,51,58,61,64,65,68-70,72], six reports [33,38,39,71,76,77], and one case-control study [60]) had data to 
calculate the standardised prevalence ratio of COVID-19 for the identified race categories in the general com-
munity. The pooled prevalence ratio for Blacks was 1.79 (95% CI = 1.59, 1.99; I2 = 99.9%, P < 0.001) (Figure 
2, Panel A), Hispanics 1.78 (95% CI = 1.63, 1.94; I2 = 99.9%, P < 0.001) (Figure 2, Panel B), Other race groups 
1.43 (95% CI = 1.19, 1.67; I2 = 100.0%, P < 0.001) (Figure 2, Panel C), and Whites 0.70 (95% CI = 0.64, 0.77; 
I2 = 99.9%, P < 0.001) (Figure 2, Panel D).
Figure 2. Standardised prevalence ratio (SPR) Forest Plots of COVID-19 by selected race groups. Panel A: Blacks. Panel B: Hispanics. Panel 
C: Other race groups. Panel D: Whites.
Figure 2. Figure 2b. 
Figure 2d. Figure 2c. 
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As shown in Figure 3, the overall pooled COVID-19 preva-
lence ratio for all population was 1.36 (95% CI = 1.29-1.43; 
I2 = 99.97%, P < 0.001). Subgroup analysis showed that UK 
had the highest of COVID-19 prevalence ratio, 1.86 (95% 
CI = 1.53, 2.19), followed by USA, 1.32 (95% CI = 1.53, 
2.19) and Brazil, 0.92 (95% CI = 0.68, 1.17). The COVID-19 
prevalence ratio reported in studies published between the 
year 2020 and 2021 were 1.40 (95% CI = 1.30, 1.50) and 
1.32 (95% CI = 1.21, 1.42), respectively. Cohort studies re-
ported the highest COVID-19 prevalence ratio of 1.41 (95% 
CI = 1.32, 1.51) followed by reports 1.35 (95% CI = 1.19, 
1.52) and cross-sectional studies 1.31 (95% CI = 1.10, 1.53).
COVID-19 hospitalisation ratio
Thirty-six studies (48.6%) (six reports [7,33,38,39,88], 
twenty-six cohorts [16,28-32,36,40,41,43-50,59,69,78-
81,84,87,88], three cross-sectional [35,42,86], and one 
case-control [60]) reported data with information on hos-
pitalisation by race. The pooled estimate of hospitalisa-
tion ratio among Blacks was 1.87 (95% CI = 1.69, 2.04; 
I2 = 99.5%, P < 0.001) (Figure 4, Panel A), Hispanics 1.32 
(95% CI = 1.08, 1.55; I2 = 99.1%, P < 0.001) (Figure 4, Panel 
B), Other race groups 1.12 (95% CI = 0.89, 1.35; I2 = 99.7%, 
P < 0.00) (Figure 4, Panel C), and Whites 0.74 (95% 
CI = 0.65, 0.82; I2 = 99.7%, P < 0.001) (Figure 4, Panel D).
The pooled overall hospitalisation ratio was 1.23 (95% CI = 1.16, 1.29; I2 = 99.67%, P < 0.001) (Figure 5). 
Country level analysis showed that UK experienced the highest hospitalisation ratio 1.64 (95% CI = 1.38, 
1.90) followed by USA 1.22 (95% CI = 1.13, 1.31) and Brazil 1.01 (95% CI = 0.96, 1.06). Analysis by study 
designs found that cohort studies reported the highest hospitalisation ratio, 1.26 (95% CI = 1.18, 1.33), fol-
lowed by cross-sectional 1.03 (95% CI = 0.87, 1.18), reports 1.23 (95% CI = 0.99-1.46) and case-control 0.95 
(95% CI = 0.60, 1.31).
COVID-19 mortality ratio
Forty-two studies (56.8%) (twenty-nine cohorts [12,28-32,34,36,40,41,43-50,52-57,89,90,93,96], four re-
ports [38,39,41,90] and nine cross-sectional studies [35,42,51,58,91,94,95,97,98]) reported data with infor-
mation to determine mortality rates by race groups. Figure 6 presents the forest plots for mortality ratio by 
race. The plots showed that the pooled estimate for the mortality ratio in Blacks was 1.68 (95% CI = 1.52, 1.83; 
I2 = 99.5%, P < 0.00) (Figure 6, Panel A), Hispanics 0.94 (95% CI = 0.84, 1.05; I2 = 98.2%, P < 0.00) (Figure 6, 
Panel B), Other race groups 1.06 (95% CI = 0.89, 1.23; I2 = 99.8%, P < 0.00) (Figure 6, Panel C), and Whites 
0.82 (95% CI = 0.78, 0.87; I2 = 99.1%, P < 0.00) (Figure 6, Panel D).
The overall pooled mortality ratio for all population shown in Figure 7 was 1.13 (95% CI = 1.07, 1.1.20; 
I2 = 99.75%, P < 0.00). Mortality ratio by country was highest for UK 1.33 (95% CI = 1.10, 1.57), followed by 
USA 1.12 (95% CI = 1.05, 1.19), and Brazil 0.98 (95% CI = 0.98, 1.05). Report studies had the highest mortal-
ity ratio 1.42 (95% CI = 1.03, 1.82), followed by cohort 1.10 (95% CI = 1.05, 1.15), and cross-sectional 1.06 
(95% CI = 0.90, 1.22).
Meta-analysis and regression
Table 1 shows the mean difference in COVID-19 outcomes for prevalence, hospitalisation, and mortality ra-
tio. It was found that the prevalence ratio between Blacks and Whites was significant, -1.09 (95% CI = -1.28, 
-0.90; P < 0.000). A significant finding was also observed between Blacks and Other race groups, -0.35 (95% 
CI = -0.55, -0.16; P < 0.000). However, the difference in COVID-19 prevalence ratio between Blacks and His-
panics was not significant, 0.11 (95% CI = -0.12, 0.34; P = 0.34). For the mean difference in prevalence ratio 
by study designs, a significant difference was observed only between case-control and cohort study design, 
0.48 (95% CI = 0.04, 0.93; P = 0.03). No significant mean difference is prevalence ratio was found between the 
studies published in 2020 and 2021, -0.07 (95% CI = -0.22, 0.09; P = 0.39).
Figure 3. Standardised prevalence ratio (SPR) Forest plots of 
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For hospitalisation ratio, it was found that the mean difference in hospitalisation ratio in Blacks was signifi-
cantly different from Whites -1.11 (95% CI = -1.31, -0.91; P < 0.001), Hispanics -0.49 (95% CI = -0.73, -0.24; 
P < 0.001), and Other race groups -0.77 (95% CI = -0.97, -0.56; P < 0.001). Intercountry analysis showed 
COVID-19 mean difference in hospitalisation ratio was significant between Brazil and UK 0.67 (0.24, 1.09; 
P < 0.001) but not between Brazil and USA 0.11 (95% CI = -0.26, 0.49; P = 0.560). The mean difference in hos-
pitalisation ratios between study designs were not significant.
The mean difference in mortality ratio between Blacks and Hispanics -0.65 (95% CI = -0.83, -0.47; P < 0.00), 
Blacks and Whites -0.82 (95% CI = -0.97, -0.68; P < 0.001), Blacks and Other race groups -0.60 (95% CI = -0.75, 
-0.44; P < 0.00) were all significant. Country level analysis showed that the mean difference between Bra-
zil and UK was significant 0.27 (95% CI = 0.01, 0.53; P = 0.04), but no difference existed between Brazil 
and USA 0.13 (95% CI = -0.10, 0.35; P = 0.28). Analysis for study design found that the mean difference 
Figure 4. Standardised hospitalisation ratio (SHR) Forest plots of COVID-19 by selected race groups. Panel A: Blacks. Panel B: Hispanics. 
Panel C: Other race groups. Panel D: Whites.
Figure 4. Figure 4b. 
Figure 4d. Figure 4c. 
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in mortality ratio between cohorts and reports was signifi-
cant, 0.26 (95% CI = 0.05, 0.46; P = 0.01) but not between 
cohorts and cross-sectional studies, -0.07 (95% CI = -0.21, 
0.07; P = 0.32).
Publication bias
Following correction for publication bias (Appendix S1-S3 
and Figures S1-S3 in the Online Supplementary Docu-
ment), the prevalence ratio among Blacks and Hispanics 
remained high; 1.38 (95% CI = 1.19, 1.57) for Blacks and 
1.59 (95% CI = 1.43, 1.75) for Hispanics compared to 0.69 
(0.62, 0.75) for Whites and 1.01 (95% CI = 0.83, 1.37) for 
Other race groups. For hospitalisation ratio, Blacks and His-
panics continued to have a high hospitalisation ratio even 
when corrected for publication bias compared to Whites and 
Other race groups. For example, the hospitalisation ratio for 
Black was 1.42 (95% CI = 1.25, 1.59), Hispanics 1.32 (1.08-
1.55) compared to 0.67 (95% CI = 0.59, 0.75) for Whites 
and 0.74 (0.49, 0.98) for Other race groups. The mortality 
ratio for Blacks remained high, 1.32 (1.17, 1.45), compared 
to Hispanics 0.82 (95% CI = 0.70, 0.93), Whites 0.82 (95% 
CI = 0.78, 0.87) and Other race groups 0.83 (95% CI = 0.67, 
0.99) following correction for publication bias.
DISCUSSION
The reviewed studies showed that COVID-19 significantly impacted Blacks across all the outcomes measured 
compared to Whites. The study found that the prevalence ratios in Blacks were 156% higher than in Whites, 
for Hispanics were 154% higher, and for Other race groups were 104% higher. There was a significant differ-
ence between prevalence ratios in Blacks and Whites and Other race groups but not Hispanics. Hospitalisation 
ratios in Blacks were 153% higher than in Whites, for Hispanics were 78% higher, and for Other race groups 
were 51% higher. A significant difference was found between hospitalisation in Blacks and Hispanics, Whites 
and Other race groups. Deaths in Blacks were 105% higher than in Whites, Hispanics were 15% higher, and 
Other race groups were 29% higher. Mortality in Blacks was significantly different from Whites, Hispanics, and 
Other race groups. Intercountry differences were also observed regarding prevalence ratios of COVID-19. The 
prevalence ratio in the USA was 102% higher than Brazil’s, and UK’s was 43% higher than Brazil’s. Although 
Blacks and Hispanics experienced a similar burden of COVID-19, Blacks had higher hospitalisation and mor-
tality ratios than Hispanics, Whites and Other race groups.
The identified racial disparities in prevalence, hospitalisations and mortality ratio from COVID-19 could be 
attributed to several reasons. It could be that Blacks, Hispanics, and Other racial groups experience higher so-
cioeconomic disadvantages that increase their risk of contracting COVID-19. People in higher socioeconom-
ic status and affluent neighbourhoods have been reported to be less likely to acquire COVID-19 infection, 
whereas social and economic disadvantages have been associated with higher COVID-19 infections [99,100].
Evidence suggests that racial minorities in urban settings tend to live in more crowded conditions and are 
more likely to be employed in public-facing occupations (for example, services and transportation), making 
practising social distancing practically impossible [13,15,101]. For example, one study found that Blacks and 
Latinos working in essential services experienced higher COVID-19 mortality rates than Whites [102]. The 
authors observed that many Blacks held the top nine essential jobs that exposed them to the risk of catching 
COVID-19, increasing the potentials of infecting their families. Another study found that frontline jobs main-
ly occupied by Blacks and Hispanics were risk factors to COVID-19 [103]. Despite racial minorities being at 
increased risk of exposure to the virus, they experience increased barriers to testing, such as health care ac-
cess, which contributes to delays in obtaining testing until they are in a more serious condition resulting in 
poor health outcomes [101].
Structural racism as a key determinant of population health can also explain the disproportionate burdens of 
COVID-19 found among racial minorities across the outcomes measured in the current study [104]. While 
Figure 5. Standardised hospitalisation ratio (SHR) Forest plots of 
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there are differences between and within countries relating to the experience of structural racism and health 
inequities because of differences in policies and forces that facilitate these issues, these systems of oppression 
can lead to health inequities because of experienced disadvantages and lack of opportunities [105,106].
Blacks, Hispanics, and Other minority racial populations experience disproportionately higher rates of other 
underlying health conditions, making them more vulnerable to COVID-19. For example, a report found that 
neighbourhoods with higher poverty rates occupied by Blacks and Hispanics experienced disproportionate 
diabetes and hypertension comorbidities and higher rates of COVID-19 infections [103]. Other studies have 
Figure 6. Standardised mortality ratio (SMR) Forest plots of COVID-19 by selected race groups. Panel A: Blacks. Panel B: Hispanics. Panel 
C: Other race groups. Panel D: Whites.
Figure 6. Figure 6b. 
Figure 6d. Figure 6c. 































www.jogh.org • doi: 10.7189/jogh.11.05015 9 2021  •  Vol. 11  •  05015
shown that comorbidities such as obesity and cardiovascu-
lar diseases, where Blacks and Others are disproportionate-
ly overrepresented, were a risk factor for COVID-19 relat-
ed mortality [6,107-109]. It may also be that older Blacks, 
Hispanics and Other racial minority groups have higher co-
morbidities than Whites, increasing their risks to COVID-19. 
Older age, regardless of race, has, however, been identified 
as a risk factor to COVID-19 [107,110,111].
Other factors, such as underlying health conditions and 
old age, could have contributed to the increased risk of 
COVID-19 in minority populations [42,60,112,113]. How-
ever, many underlying health conditions result from years 
of systemic inequities in social determinants of health, in-
cluding poor housing, lack of employment, low income, 
racism, poor neighbourhood, and poor working and living 
conditions experienced by minority populations in western 
countries [112,114-117]. For example, residents in poor 
neighbourhoods with a poorly built environment to facil-
itate physical activities are less likely to participate in phys-
ical activities and are more likely to live sedentary lifestyles 
[118]. Sedentary lifestyles and lack of physical activities are 
risk factors for cardiovascular-related health conditions, in-
cluding but not limited to hypertension, diabetes, and obe-
sity [112]. In countries such as the United States, issues re-
lated to structural determinants of health are prevalent and 
disproportionately experienced by minority populations, which leads to generational inequities [99,119].
Given these findings, there is a need for a shift of focus from treating comorbidities from clinical perspectives 
only to addressing broader socioeconomic and structural determinants of health disadvantages experienced by 
most Blacks, Hispanics and Other minority groups in western countries [120]. Unprecedentedly, COVID-19 
has exposed the social disadvantages that Blacks, Hispanics and Other minority populations continue to ex-
perience because of racism, discrimination, and systemic institutional policy of racial suppression in western 
countries [104]. Governments and policymakers have an opportunity to turn the course of health inequities 
in minority populations by investing in programs that facilitate equity in disadvantaged communities for im-
proved health outcomes.
Figure 7. Standardised mortality ratio (SMR) Forest plots of 
COVID-19 by race, country, year, and study design.
Figure 7. 
Table 1. Meta-regression of Mean difference for prevalence, hospitalisation, and mortality ratios by subgroups
Outcomes Parameters Mean difference (95% CI) P value
Prevalence ratio
Race Black Ref .
Hispanics 0.11 (-0.12, 0.34) 0.343
Other -0.35 (-0.55, -0.16) <0.001
White -1.09 (-1.28, -0.90) <0.001
Country Brazil Ref .
UK 0.91 (0.56, 1.26) <0.001
USA 0.19 (-0.13, 0.51) 0.248
Year 2020 Ref .
2021 -0.07 (-0.22, 0.09) 0.387
Design Case-control Ref .
Cohort 0.48 (0.04, 0.93) 0.033
Cross-sectional 0.25 (-0.22, 0.72) 0.302
Report 0.24 (-0.23, 0.71) 0.312
Hospitalisation ratio
Race Black Ref .
Hispanics -0.49 (-0.73, -0.24) <0.001
Other -0.77 (-0.97, -0.56) <0.001
White -1.11 (-1.31, -0.91) <0.001
Outcomes Parameters Mean difference (95% CI) P value
Country Brazil Ref .
UK 0.67 (0.24, 1.09) <0.001
USA 0.11 (-0.26, 0.49) 0.558
Design Case-control 0.00 (0.00, 0.00) .
Cohort 0.30 (-0.12, 0.72) 0.158
Cross-sectional 0.11 (-0.42, 0.63) 0.691
Report 0.21 (-0.24, 0.65) 0.366
Mortality ratio
Race Black Ref .
Hispanics -0.65 (-0.83, -0.47) <0.001
Other -0.60 (-0.75, -0.44) <0.001
White -0.82 (-0.97, -0.68) 0.00
Country Brazil Ref .
UK 0.27 (0.01, 0.53) 0.039
USA 0.13 (-0.10, 0.35) 0.276
Design Cohort Ref .
Cross-sectional -0.07 (-0.21, 0.07) 0.318
Report 0.26 (0.05, 0.46) 0.014
































2021  •  Vol. 11  •  05015 10 www.jogh.org •  doi: 10.7189/jogh.11.05015
Limitations and strengths
There are a few limitations to consider when interpreting the finding from this article. The included studies 
used different study designs and populations that could have influenced the selection of study participants 
and protocols, and thus, the findings. Some studies did not clearly describe whether race was self-reported 
and could have misclassified the race of some patients, which could have led to under-or over-reporting of 
COVID-19 outcomes. The included studies did not have data on many moderators, and we could not conduct 
a meta-analysis controlling for them. The different sources of data used by the different studies (for example, 
hospital data and sentinel data), differences in specificity and sensitivity of tests used could have contributed 
to the high heterogeneity observed among the studies, and the differences in the ascertainment of death out-
comes are important limitations to note. Lastly, we did not search for all the grey literature, which could have 
inadvertently led to the omission of additional potential studies. It is, therefore, important to interpret our 
findings with these limitations in mind.
An important strength of this paper is its methodologically rigorous analysis that involved correcting for pub-
lication bias and synthesising the findings to highlight the extent of the disproportionate burden of COVID-19 
in racial minority groups. This means that the findings cannot be attributed to publication bias which ensures 
confidence in the finding. Another strength of this review is its use of meta-regression analysis controlling for 
the different parameters, and this was vital to compare the results by sub-groups. Our findings highlight the 
disproportionate burdens of COVID-19 outcomes among the selected race groups.
CONCLUSIONS
The burden of COVID-19 in terms of prevalence, hospitalisation, and mortality rate was disproportionately 
higher among Blacks and Hispanics compared with Whites. These findings point to the systemic disadvantag-
es experienced by racial minority populations and highlight the need to address inequities in these commu-
nities by developing programs that improve overall health outcomes. Further work and more well-designed 
longitudinal studies are needed to expand the knowledge on racial differences in COVID-19 outcomes and to 
identify the social determinants of health shaping the disparities in the outcome of COVID-19 among racial 
minority populations.
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